|
Volumn 377, Issue 17, 2017, Pages 1605-1607
|
HIV drug resistance — An emerging threat to epidemic control
a b |
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIRETROVIRUS AGENT;
CABOTEGRAVIR;
DOLUTEGRAVIR;
EFAVIRENZ;
EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
INTEGRASE INHIBITOR;
NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR;
PROTEINASE INHIBITOR;
ANTIVIRAL RESISTANCE;
DRUG EFFICACY;
GOVERNMENT;
HEALTH CARE DELIVERY;
HEALTH CARE ORGANIZATION;
HEALTH PROGRAM;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
PRIORITY JOURNAL;
PROCESS MONITORING;
PUBLIC HEALTH SERVICE;
SHORT SURVEY;
TREATMENT OUTCOME;
UNITED STATES;
VIRUS INHIBITION;
COMMUNICABLE DISEASE CONTROL;
DRUG EFFECTS;
EPIDEMICS;
GLOBAL HEALTH;
HIV INFECTIONS;
HUMAN IMMUNODEFICIENCY VIRUS;
WORLD HEALTH ORGANIZATION;
ANTI-RETROVIRAL AGENTS;
COMMUNICABLE DISEASE CONTROL;
DRUG RESISTANCE, VIRAL;
EPIDEMICS;
GLOBAL HEALTH;
HIV;
HIV INFECTIONS;
HUMANS;
WORLD HEALTH ORGANIZATION;
|
EID: 85032471759
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMp1710608 Document Type: Short Survey |
Times cited : (126)
|
References (5)
|